Diagnostic values of SCC, CEA, Cyfra21-1 and NSE for lung cancer in patients with suspicious pulmonary masses: A single center analysis

Chu, Xiangyang; Hou, Xiaobin; Song, Weian; Xue, Zhiqiang; Wang, Bo; Lian-bin, Zhang

doi:10.4161/cbt.11.12.15526

Cited by 72 publications

(67 citation statements)

References 18 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, they found that the AUC was 0.855 for HE4. 19,20 Our results regarding the diagnostic accuracy of HE4 (both sensitivity and specificity: 87.1% and AUC: 0.921) are much better than the results of this meta analysis, which International Journal of Hematology and Oncology indicates that HE4 is a promising biomarker for NSCLC diagnosis.…”

Section: -contrasting

confidence: 41%

Serum Human Epididymis Protein 4 (HE4) As A Diagnostic And Follow-Up Biomarker in Patients With Non-Small Cell Lung Cancer

Kumbasar¹

2017

UHOD

View full text Add to dashboard Cite

Early detection of non-small cell lung cancer (NSCLC) cases is crucial since nearly one third of them are unresectable during diagnosis and also the recurrence rates are high following treatment. Thus, in this study we aimed to evaluate both the diagnostic performance and the post-resection progress of serum Human epididymis protein 4 (HE4) in patients with NSCLC. Thirty-one patients who had benign lung disease (group 1) were matched to the same number of patients with resectable NSCLC (group 2). Serum HE4 levels were measured at the time of diagnosis and following surgery -at post-operative 1st month (only in group 2). The serum HE4 in NSCLC group was significantly higher than that of the benign group (89.70 (58.10-397.00) pmol/L and 42. 60 (28.10-198.90) pmol/L, respectively; p< 0.001). HE4 levels in NSCLC group were significantly decreased from 89.70 (58.10-397.00) to 71.50 (41.70-232.30) pmol/L following pulmonary resection (p< 0.001). In advanced stages (III and IV) the decrease in serum HE4 levels (25.30 (10.50-164.70) was significantly higher than the decrease in early stages ); p= 0.025). ROC analysis showed the area under the curve (AUC) of HE4 was 0.921 (95% CI, 0.843-0.998), (p< 0.001) and both the sensitivity and specificity of HE4 as a biomarker was 87.1%. Our data demonstrated that HE4 is a potential biomarker for the diagnosis of NSCLC with high sensitivity and specificity and could also be used to detect recurrences following resection.Keywords: HE4, Non-small cell lung cancer, Biomarker ÖZET Küçük Hücreli Dışı Akciğer Kanserinin Tanı ve Takip Aşamasında HE4 Proteininin Etkinliğinin DeğerlendirilmesiKüçük hücreli dışı akciğer kanserinde (KHDAK) hastaların yaklaşık üçte biri tanı anında anrezektabl olduğundan erken tanı oldukça önemlidir. Ayrıca tedavi sonrasında rekürrens oranı oldukça yüksektir. Bu çalışmanın amacı, KHDAK'da İnsan Epididimis Proteini 4'ün (HE4) preoperatif tanısal performansının ve cerrahi rezeksiyon uygulanan hastalarda postoperatif etkinliğinin belirlenmesidir. Hastalar, benign akciğer hastalığı olanlar (grup I, n= 31) ve KHDAK nedeniyle cerrahi rezeksiyon uygulananlar hastalar (grup 2, n= 31) olmak üzere iki ana gruba ayırıldı. Cerrahi uygulanan grupta preoperatif ve postoperatif 1. aydaki serum HE4 değerleri kaydedildi. KHDAK grubunda preoperatif dönemde ölçülen ortanca HE4 değerleri, benign grupta ölçülen değerlerden istatistiksel olarak anlamlı ölçüde yüksek bulundu (89.70 (58.10-397.00) pmol/L ve 42. 60 (28.10-198.90) pmol/L, sırası ile; p< 0.001). Cerrahi uygulanan hastaların preoperatif ve postoperatif değerleri karşılaştırıldığında HE4 seviyelerinin postoperatif dönemde istatistiksel olarak anlamlı şekilde düştüğü gözlendi (89.70 (58.10-397.00) ile 71.50 (41.70-232.30) pmol/L; p< 0.001). İleri evrelerdeki (evre III-IV) düşüşün erken evrelere (evre I-II) göre anlamlı derecede daha fazla olduğu görüldü (25.30 (10.50-164.70) ile 14.60 (-14.20-133.60); p= 0.025). HE4'ün tanısal etkinliği ROC analizi ile değerlendirildiğinde eğri altında kalan alan 0.921 (95% CI, 0....

show abstract

Section: -contrasting

confidence: 41%

Serum Human Epididymis Protein 4 (HE4) As A Diagnostic And Follow-Up Biomarker in Patients With Non-Small Cell Lung Cancer

Kumbasar¹

2017

UHOD

View full text Add to dashboard Cite

show abstract

“…Tumor necrosis factor (TNF) a is one of the most potent pro-inflammatory cytokines produced in the tumor microenvironment (Takahashi et al, 2010). Earlier studies illustrated the significance of these tumor markers in the detection, prognosis and follow-up of lung cancer (Niewoehner and Rubins, 2003;Emin et al, 2010;Chu et al, 2011). However, the roles of these tumor markers in the diagnosis of coke oven workers are remain to be determined due to their relatively low sensitivity.…”

Section: Introductionmentioning

confidence: 99%

“…Also, long-term exposure to PAHs had been reported to be associated with high incidence of lung cancer in coke oven workers (Wang et al, 2010;National Toxicology Program, 2011). As for serum tumor markers, including cytokeratin 19 fragments (Cyfra21-1), squamous cell carcinoma antigen (SCC) and neuron specific enolase (NSE), have been extensively studied in lung cancer (Niewoehner and Rubins, 2003;Emin et al, 2010;Chu et al, 2011). Accumulating evidence unravels the molecular mechanisms by which inflammatory responses promote tumor progression.…”

Section: Introductionmentioning

confidence: 99%

Synergistic Increase of Oxidative Stress and Tumor Markers in PAH-Exposed Workers

Gao

Chen²,

Li³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Tumor markers, including carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), neuron-specific enolase (NSE), squamous cell carcinoma antigen (SCCAg) and cytokeratin-19 fragments (Cyfra21-1), are clinically applied for the early detection of lung cancer (4,5). However, the sensitivity and specificity of these biomarkers are not adequate (6)(7)(8). Combined detection using a panel of biomarkers can improve the sensitivity and accuracy in lung cancer diagnosis, but consequently results in a lower specificity and increased financial burden to patients.…”

Section: Introductionmentioning

confidence: 99%

Transthyretin as a potential biomarker for the differential diagnosis between lung cancer and lung infection

et al. 2014

View full text Add to dashboard Cite

Abstract. Satisfactory biomarkers for screening and early diagnosis of lung cancer remain scarce and require further investigation. The aim of the present study was to examine the changes of the biochemical and protein composition in the serum and pleural effusion from lung cancer and lung infection (bacterial pneumonia) patients. A total of 92 patients with lung cancer, 38 with bacterial pneumonia and 42 healthy controls were enrolled in the study. The serum levels of cholesterol, apolipoprotein A and transthyretin (TTR) in the lung cancer patients were higher than that of the lung infection patients (P<0.05). The levels of TTR were higher, whereas the activity of adenosine deaminase (ADA) was lower in the pleural effusion from the lung cancer patients compared to the lung infection patients (P<0.05). Furthermore, the pleural effusion/serum TTR ratios in the lung cancer patients were higher, whereas the ratios of ADA were lower (P<0.05). By matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis, four major peaks corresponding to native TTR, Sul-TTR, Cys-TTR and Cysgly-TTR were observed in the serum of the lung cancer and lung infection patients. A significant increase was found in the proportion of Cysgly-TTR in the pleural effusion from the patients with lung cancer. The data indicated that a combination of pleural effusion/serum TTR ratios and modified TTR may be beneficial for the differential diagnosis between lung cancer and lung infection. IntroductionLung cancer is one of the most common malignant tumors worldwide, with a 5-year survival rate of 14% (1). Thus far, the statistics for cancer occurrence and outcome show that lung cancer remains a primary cause of mortality from cancer (2,3). Since the incidence and mortality of lung cancer increases significantly every year, it represents a major economic burden to society. Currently, the screening and early diagnosis of lung cancer in clinics relies mainly on magnetic resonance imaging (MRI) and computed tomography (CT) imaging, whereas the final diagnosis is established on the basis of histopathological examination results. The early clinical manifestations of lung cancer patients are relatively mild and not typical, easily overlooked or confused with benign inflammatory disease, such as lung infection. Therefore, early identification and diagnosis of lung cancer is significant since lung cancer may be curable in its early stages (1).Thus far, increasing attention has focused on searching for improved biomarkers that function not only to detect lung cancer at an early stage but also to explore the molecular mechanisms that underlie cancer development. Tumor markers, including carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), neuron-specific enolase (NSE), squamous cell carcinoma antigen (SCCAg) and cytokeratin-19 fragments (Cyfra21-1), are clinically applied for the early detection of lung cancer (4,5). However, the sensitivity and specificity of these biomarkers are not adequate (6-8). Combined detection usi...

show abstract

Diagnostic values of SCC, CEA, Cyfra21-1 and NSE for lung cancer in patients with suspicious pulmonary masses: A single center analysis

Cited by 72 publications

References 18 publications

Serum Human Epididymis Protein 4 (HE4) As A Diagnostic And Follow-Up Biomarker in Patients With Non-Small Cell Lung Cancer

Serum Human Epididymis Protein 4 (HE4) As A Diagnostic And Follow-Up Biomarker in Patients With Non-Small Cell Lung Cancer

Synergistic Increase of Oxidative Stress and Tumor Markers in PAH-Exposed Workers

Transthyretin as a potential biomarker for the differential diagnosis between lung cancer and lung infection

Contact Info

Product

Resources

About

Diagnostic values of SCC, CEA, Cyfra21-1 and NSE for lung cancer in patients with suspicious pulmonary masses: A single center analysis

Cited by 72 publications

References 18 publications

Serum Human Epididymis Protein 4 (HE4) As A Diagnostic And Follow-Up Biomarker in Patients With Non-Small Cell Lung Cancer

Serum Human Epididymis Protein 4 (HE4) As A Diagnostic And Follow-Up Biomarker in Patients With Non-Small Cell Lung Cancer

Synergistic Increase of Oxidative Stress and Tumor Markers in PAH-Exposed Workers

Transthyretin as a potential biomarker for the differential diagnosis between lung cancer and lung infection

Contact Info

Product

Resources

About

Serum Human Epididymis Protein 4 (HE4) As A Diagnostic And Follow-Up Biomarker in Patients With Non-Small Cell Lung Cancer

Serum Human Epididymis Protein 4 (HE4) As A Diagnostic And Follow-Up Biomarker in Patients With Non-Small Cell Lung Cancer